Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients
- 749 Downloads
Two-tier serology is often used to confirm a diagnosis of Lyme disease. One hundred and four patients with physician diagnosed erythema migrans rashes had blood samples taken before and after 3 weeks of doxycycline treatment for early Lyme disease. Acute and convalescent serologies for Borrelia burgdorferi were interpreted according to the 2-tier antibody testing criteria proposed by the Centers for Disease Control and Prevention. Serostatus was compared across several clinical and demographic variables both pre- and post-treatment. Forty-one patients (39.4 %) were seronegative both before and after treatment. The majority of seropositive individuals on both acute and convalescent serology had a positive IgM western blot and a negative IgG western blot. IgG seroconversion on western blot was infrequent. Among the baseline variables included in the analysis, disseminated lesions (p < 0.0001), a longer duration of illness (p < 0.0001), and a higher number of reported symptoms (p = 0.004) were highly significantly associated with positive final serostatus, while male sex (p = 0.05) was borderline significant. This variability, and the lack of seroconversion in a subset of patients, highlights the limitations of using serology alone in identifying early Lyme disease. Furthermore, these findings underline the difficulty for rheumatologists in identifying a prior exposure to Lyme disease in caring for patients with medically unexplained symptoms or fibromyalgia-like syndromes.
KeywordsBorrelia burgdorferi Lyme disease Seroconversion
- 1.Centers for Disease Control and Prevention (2013) Notice to readers: final 2012 reports of nationally notifiable infectious diseases. Morb Mortal Wkly Rep 62:669–682Google Scholar
- 2.Bacon R, Kugeler K, Mead P (2008) Surveillance for lyme disease—United States, 1992–2006. Morb Mortal Wkly Rep 57:1–9Google Scholar
- 4.Wormser GP, Nowakowski J, Nadelman RB et al (2008) Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clin Vaccine Immunol 15:1519–1522. doi:10.1128/CVI.00109-08 CrossRefPubMedCentralPubMedGoogle Scholar
- 6.Centers for Disease Control and Prevention (1995) Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. Morb Mortal Wkly Rep 44:590–591Google Scholar